Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck

被引:28
作者
Bernier, Jacques [1 ]
机构
[1] Genolier Swiss Med Network, Dept Radiat Oncol, Radiooncol Div, CH-1272 Genolier, Switzerland
来源
NATURE CLINICAL PRACTICE ONCOLOGY | 2008年 / 5卷 / 12期
关键词
cetuximab; epidermal growth factor receptor; metastatic; recurrent; squamous cell carcinoma of the head and neck;
D O I
10.1038/ncponc1228
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) have a poor prognosis, particularly those whose disease has progressed on previous platinum-containing therapy. The epidermal growth factor receptor (EGFR) is expressed at very high levels in SCCHN and is associated with a poor prognosis. Several phase II-III studies have shown that the EGFR-targeting monoclonal antibody, cetuximab, offers clinical benefit for patients with SCCHN. Cetuximab monotherapy is active in patients whose cancer progresses on platinum-containing therapy. Tumor response and patient survival are in excess of what is achieved with commonly used therapies in this setting. Addition of a platinum regimen to cetuximab in patients with disease that progresses on platinum seems to confer no further benefit over cetuximab alone, either in terms of response rate or survival. In the first-line setting, cetuximab plus platinum and 5-fluorouracil significantly prolongs overall survival compared with platinum and 5-fluorouracil alone. The superior survival observed with cetuximab compared with platinum-based treatment demonstrates that cetuximab is the most active treatment for recurrent and/or metastatic SCCHN, and is of particular clinical significance.
引用
收藏
页码:705 / 713
页数:9
相关论文
共 51 条
[1]   Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck - An analysis of two Eastern Cooperative Oncology Group randomized trials [J].
Argiris, A ;
Li, Y ;
Forastiere, A .
CANCER, 2004, 101 (10) :2222-2229
[2]   Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].
Baselga, J ;
Pfister, D ;
Cooper, MR ;
Cohen, R ;
Burtness, B ;
Bos, M ;
D'Andrea, G ;
Seidman, A ;
Norton, L ;
Gunnett, K ;
Falcey, J ;
Anderson, V ;
Waksal, H ;
Mendelsohn, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914
[3]   Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck [J].
Baselga, J ;
Trigo, JM ;
Bourhis, J ;
Tortochaux, J ;
Cortés-Funes, H ;
Hitt, R ;
Gascón, P ;
Arnellal, N ;
Harstrick, A ;
Eckardt, A .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5568-5577
[4]  
Baselga J, 2001, EUR J CANCER, V37, pS16
[5]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[6]   Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck [J].
Bourhis, Jean ;
Rivera, Fernando ;
Mesia, Ricard ;
Awada, Ahmad ;
Geoffrois, Lionel ;
Borel, Christian ;
Humblet, Yves ;
Lopez-Pousa, Antonio ;
Hitt, Ricardo ;
Vega Villegas, M. Eugenia ;
Duck, Lionel ;
Rosine, Dominique ;
Amellal, Nadia ;
Schueler, Armin ;
Harstrick, Andreas .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2866-2872
[7]   An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom [J].
Brown, Ben ;
Diamantopoulos, Alexander ;
Bernier, Jacques ;
Schoeffski, Patrick ;
Hieke, Klaus ;
Mantovani, Lorenzo ;
Launois, Robert ;
Griebsch, Ingolf ;
Robinson, Paul .
VALUE IN HEALTH, 2008, 11 (05) :791-799
[8]   Antiepidermal growth factor receptor antibodies augment cytotoxicity of chemotherapeutic agents on squamous cell carcinoma cell lines [J].
Brown, D ;
Wang, R ;
Russell, P .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2000, 122 (01) :75-83
[9]   Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study [J].
Burtness, B ;
Goldwasser, MA ;
Flood, W ;
Mattar, B ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8646-8654
[10]  
Chen Z, 2000, ANTICANCER RES, V20, P899